Aggrastat Inj.

Ingredient

Tirofiban Hydrochloride Hydrate　

Content

14.05mg/50ml (12.5mg/50ml as tirofiban)

Indication

Co-administration with heparin in the patients who are:
– target patients in the treatment of acute coronary syndrome (ACS)
– patients with percutaneous transluminal coronary angioplasty (PTCA) or atherectomy

It has been shown to reduce the incidence of death, myocardial infarction, or combined endpoints of refractory ischemia/recardiac procedures.

Allegra Tab. 180mg

Ingredient

Fexofenadine Hydrochloride

Content

180mg

Indication

Relief of symptoms associated with allergic skin disease (chronic idiopathic urticaria).

Allegra Tab. 30mg

Ingredient

Fexofenadine Hydrochloride

Content

30mg

Indication

Relief of symptoms associated with seasonal allergic rhinitis and allergic skin diseases (chronic idiopathic urticaria)

Amaryl M Tab.

Ingredient

Glimepiride/Metformin Hydrochloride

Content

1/250mg, 1/500mg, 2/500mg

Indication

Management of type 2 diabetes mellitus as an adjunct to diet and exercise in following cases:
-When glimepiride or metformin monotherapy is insufficient to control blood glucose level
-As an alternative to combination therapy of glimepiride and metformin

Amaryl Mex SR Tab.

Ingredient

Glimepiride/Metformin Hydrochloride

Content

2mg/500mg

Indication

Management of type 2 diabetes mellitus as an adjunct to diet and exercise in following cases:
-When sulfonylurea or metformin monotherapy is insufficient to control blood glucose level
-As an alternative to combination therapy of sulfonylurea and metformin

Amaryl Tab.

Ingredient

Glimepiride

Content

1mg, 2mg, 4mg

Indication

Management of type 2 diabetes mellitus as an adjunct to diet and exercise
1) It is administered as monotherapy
2) It is administered in combination therapy
-When oral hypoglycemic agent is insufficient to control blood glucose level, this drug can be co-administered with insulin
-When sulfonylurea or metformin monotherapy is insufficient to control blood glucose level, this drug can be co-administered with metformin

Arixtra Inj.

Ingredient

Fondaparinux Sodium

Content

2.5mg/0.5ml (pre-filled syringe)

Indication

1) Prophylaxis of venous thromboembolism in patients undergoing major orthopedic surgery of the lower limb, such as hip fracture surgery, knee surgery, or hip replacement surgery
2) Prophylaxis of venous thromboembolism in patients underwent abdominal surgery, such as abdominal cancer surgery who are deemed to have a high risk of thromboembolic complications
3) Prophylaxis of venous thromboembolism in patients with limited mobility due to acute diseases such as heart failure (NYHA class Ⅲ or Ⅳ), acute respiratory disease, acute infection or inflammatory disease and medical patients who are deemed to have a high risk of venous thromboembolism
4) Treatment of unstable angina or non-ST segment elevation myocardial infarction (UA/NSTEMI) in patients who are not covered by emergency invasive management (Percutaneous Coronary Intervention(PCI) within 120 minutes)
5) Treatment of ST segment elevation myocardial infarction (STEMI) in patients who are being treated with thrombolytic agents or initially not receiving other forms of reperfusion therapy